RELA and infection: Due to the bioactivity of TBrC mentioned above and the roles of ACE2-Spike and Mpro/3CL as well as NF-κB p65 during the infection and replication of the wildtype and mutants Delta and Omicron SARS-CoV-2 as well as the easily detectable fluorescent imaging of TBrC in vivo, TBrC has the potential for further research and development in clinical application as anti-SARS-CoV-2 drug candidate, especially for lung cancer patients with SARS-CoV-2.